PURPOSE: Multimodal therapy is a well-established approach for the treatment of sinonasal undifferentiated carcinoma (SNUC); however, the optimal sequence of the various treatments modalities is yet to be determined. This study aimed to assess the role of induction chemotherapy (IC) in guiding definitive therapy in patients with SNUC. METHODS: Ninety-five previously untreated patients diagnosed with SNUC and treated between 2001 and 2018 at The University of Texas MD Anderson Cancer Center were included in the analysis. Patients were treated with curative intent and received IC before definitive locoregional therapy. The primary end point was disease-specific survival (DSS). Secondary end points included overall and disease-free survival, disease recurrence, and organ preservation. RESULTS: A total of 95 treatment-naïve patients were included in the analysis. For the entire cohort, the 5-years DSS probability was 59% (95% CI, 53% to 66%). In patients who had partial or complete response to IC, the 5-year DSS probabilities were 81% (95% CI, 69% to 88%) after treatment with definitive concurrent chemoradiotherapy (CRT) after IC and 54% (95% CI, 44% to 61%) after definitive surgery and postoperative radiotherapy or CRT after IC (log-rank P = .001). In patients who did not experience at least a partial response to IC, the 5-year DSS probabilities were 0% (95% CI, 0% to 4%) in patients who were treated with concurrent CRT after IC and 39% (95% CI, 30% to 46%) in patients who were treated with surgery plus radiotherapy or CRT (adjusted hazard ratio of 5.68 [95% CI, 2.89 to 9.36]). CONCLUSION: In patients who achieve a favorable response to IC, definitive CRT results in improved survival compared with those who undergo definitive surgery. In patients who do not achieve a favorable response to IC, surgery when feasible seems to provide a better chance of disease control and improved survival.
PURPOSE: Multimodal therapy is a well-established approach for the treatment of sinonasal undifferentiated carcinoma (SNUC); however, the optimal sequence of the various treatments modalities is yet to be determined. This study aimed to assess the role of induction chemotherapy (IC) in guiding definitive therapy in patients with SNUC. METHODS: Ninety-five previously untreated patients diagnosed with SNUC and treated between 2001 and 2018 at The University of Texas MD Anderson Cancer Center were included in the analysis. Patients were treated with curative intent and received IC before definitive locoregional therapy. The primary end point was disease-specific survival (DSS). Secondary end points included overall and disease-free survival, disease recurrence, and organ preservation. RESULTS: A total of 95 treatment-naïve patients were included in the analysis. For the entire cohort, the 5-years DSS probability was 59% (95% CI, 53% to 66%). In patients who had partial or complete response to IC, the 5-year DSS probabilities were 81% (95% CI, 69% to 88%) after treatment with definitive concurrent chemoradiotherapy (CRT) after IC and 54% (95% CI, 44% to 61%) after definitive surgery and postoperative radiotherapy or CRT after IC (log-rank P = .001). In patients who did not experience at least a partial response to IC, the 5-year DSS probabilities were 0% (95% CI, 0% to 4%) in patients who were treated with concurrent CRT after IC and 39% (95% CI, 30% to 46%) in patients who were treated with surgery plus radiotherapy or CRT (adjusted hazard ratio of 5.68 [95% CI, 2.89 to 9.36]). CONCLUSION: In patients who achieve a favorable response to IC, definitive CRT results in improved survival compared with those who undergo definitive surgery. In patients who do not achieve a favorable response to IC, surgery when feasible seems to provide a better chance of disease control and improved survival.
Authors: Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper Journal: N Engl J Med Date: 2003-11-27 Impact factor: 91.245
Authors: Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson Journal: N Engl J Med Date: 1991-06-13 Impact factor: 91.245
Authors: Moran Amit; Samantha Tam; Ahmed S Abdelmeguid; Michael E Kupferman; Shirley Y Su; Shaan M Raza; Franco DeMonte; Ehab Y Hanna Journal: J Neurol Surg B Skull Base Date: 2017-07-31
Authors: Emily D Tanzler; Christopher G Morris; Christine A Orlando; John W Werning; William M Mendenhall Journal: Head Neck Date: 2008-05 Impact factor: 3.147
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Maria Ansari; Shan Guo; Samer Fakhri; Martin J Citardi; Angel Blanco; Maria Patino; Jamie Buryanek; Robert Amato; Ron Karni; Robert E Brown Journal: Ann Clin Lab Sci Date: 2013 Impact factor: 1.256
Authors: Abrahim Al-Mamgani; Peter van Rooij; Robert Mehilal; Lisa Tans; Peter C Levendag Journal: Eur Arch Otorhinolaryngol Date: 2012-04-03 Impact factor: 2.503
Authors: Dauren Adilbay; Cristina Valero; Conall Fitzgerald; Avery Yuan; Ximena Mimica; Piyush Gupta; Richard J Wong; Jatin P Shah; Snehal G Patel; Ian Ganly; Marc A Cohen Journal: Head Neck Date: 2022-01-25 Impact factor: 3.147
Authors: J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti Journal: J Neurooncol Date: 2020-08-12 Impact factor: 4.130
Authors: Molly E Heft Neal; Andrew C Birkeland; Apurva D Bhangale; Jingyi Zhai; Aditi Kulkarni; Susan K Foltin; Brittany M Jewell; Megan L Ludwig; Lisa Pinatti; Hui Jiang; Jonathan B McHugh; Lawence Marentette; Erin L McKean; J Chad Brenner Journal: BMC Cancer Date: 2021-05-29 Impact factor: 4.430
Authors: Stefanie Glöss; Philipp Jurmeister; Anne Thieme; Simone Schmid; Wei Y Cai; Rene N Serrette; Sven Perner; Julika Ribbat-Idel; Axel Pagenstecher; Hendrik Bläker; Ursula Keber; Christine Stadelmann; Sabrina Zechel; Pascal D Johann; Martin Hasselblatt; Werner Paulus; Christian Thomas; Hildegard Dohmen; Daniel Baumhoer; Stephan Frank; Abbas Agaimy; Ulrich Schüller; Varshini Vasudevaraja; Matija Snuderl; Cheng Z Liu; David G Pfister; Achim A Jungbluth; Ronald A Ghossein; Bin Xu; David Capper; Snjezana Dogan Journal: Am J Surg Pathol Date: 2021-09-01 Impact factor: 6.298
Authors: Kevin C Miller; John P Marinelli; Jeffrey R Janus; Ashish V Chintakuntlawar; Robert L Foote; Michael J Link; Garret Choby; Jamie J Van Gompel Journal: J Neurol Surg B Skull Base Date: 2020-01-14
Authors: Roi Dagan; Haruka Uezono; Curtis Bryant; Adam L Holtzman; Christopher G Morris; William M Mendenhall Journal: Int J Part Ther Date: 2021-06-25